[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100597862":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":37,"responsibleParty":55,"collaborators":59,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":65,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":31,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":40,"whyStopped":31,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"University of Pittsburgh","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Gamma - Glutamylcysteine","EXPERIMENTAL","Patients will receive GGC tablet 400mg orally twice a day (morning and in the afternoon).",[13],"Drug: Gamma- glutamylcysteine",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Gamma- glutamylcysteine","400 mg (two times) per day",[9],[21],"GGC",[23],{"name":24,"affiliation":5,"role":25},"Pravat K Mandal, PHD","PRINCIPAL_INVESTIGATOR",[27,33],{"name":28,"role":29,"phone":30,"phoneExt":31,"email":32},"Pravat K MANDAL, PHD","CONTACT","4126999561",null,"mandalpk@pitt.edu",{"name":34,"role":29,"phone":35,"phoneExt":31,"email":36},"Nazia Pillar, M.S","878-670-3123","naa430@pitt.edu",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"UPMC Presbyterian Hospital","RECRUITING","Pittsburgh","Pennsylvania","15213","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-79.99589,40.44062,{"lat":50,"lon":49},[53],{"name":54,"role":29,"phone":30,"phoneExt":31,"email":32},"Pravat K Mandal, PhD",{"type":56,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"SPONSOR_INVESTIGATOR","Pravat Mandal","Research Assistant Professor",[60],{"name":61,"class":62},"Waste Connections Inc","UNKNOWN","100597862","phase-1-enrichment-of-glutathione-using-gamma-glutamylcysteine-supplementation-in-parkinsons-disease-patients-100597862",false,"NCT07064005","Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients.","Brain Glutathione (GSH) Enrichment Through Gamma-glutamylcysteine (GGC) Supplementation in Early Parkinson's Disease Patients for Reduction of Extrapyramidal Motor Disturbances and Halting Cognition Decline: A Pilot Trial","PDGSH","Inclusion Criteria:\n\n* Confirmed Parkinson's Disease diagnosis.\n* Montreal Cognitive Assessment (MoCA) greater than or equal to 26.\n* Age (50 to 80 years of age).\n* Ability to read and write in English.\n\nExclusion Criteria:\n\n* Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments in the eyes, skin, or body.\n* Subjects with claustrophobia.\n* Patients with a clinical diagnosis of Parkinson's disease dementia or dementia with Lewy bodies.\n* Subjects with a history of cancer.\n* Subjects with active psychosis or delirium.\n* Subjects with chronic kidney (creatinine \\> 1.5mg\u002FdL) or liver disease (AST ≥ 1.5 ULN; ALT ≥ 1.5 ULN) within 30 days prior to enrolment.\n* Subjects on antioxidant therapy (ashwagandha, gingko biloba or N-acetylcysteine) or illicit drug abuse\u002Fdependence (cocaine, heroin, marijuana, or fentanyl).\n* Subjects with previous traumatic head injury.","ALL","50 Years","80 Years",{"count":75,"type":76},12,"ESTIMATED","INTERVENTIONAL",[79],"PHASE1","This study is designed l to evaluate the effects of GGC oral supplementation in early Parkinson's disease (PD) patients. The main objectives of the study are to evaluate:\n\n1. To study the enrichment of master antioxidant, glutathione (GSH) levels in brain and blood of these PD patients compared to baseline due to GGC supplementation.\n2. To study the changes in motor function, cognitive skills in PD patients due to GGC oral supplementation\n3. To study impact of GGC on gut health on the PD patients.",[82],"Parkinsons Disease (PD)",[84,85,86,21,87,88,89,90],"Blood","Brain","MR Spectroscopy","Glutathione","Parkinsons disease","Oxidative stress","Brain Iron","2026-05-01",{"date":93,"type":94},"2026-05-04","ACTUAL",{"date":96,"type":94},"2026-03-23",{"date":98,"type":76},"2027-11-27",{"name":57,"class":6},1]